ArticleInternational journal of nanomedicine2016
Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
Article in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Impact of nanoparticles on amyloid β-induced Alzheimer's disease, tuberculosis, leprosy and cancer: a systematic review.Bioscience reports · 2023Pooled it
- Mannosylated fisetin/carveol lipid nanocapsules: brain-targeted dual therapy for modulation of epileptogenesis and cognitive deficits.Drug delivery and translational research · 2026Article
- Engineering mannose-functionalized nanostructured lipid carriers by sequential design using hybrid artificial intelligence tools.Drug delivery and translational research · 2025Article
- Leprosy: Comprehensive insights into pathology, immunology, and cutting-edge treatment strategies, integrating nanoparticles and ethnomedicinal plants.Frontiers in pharmacology · 2024Review
- Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.Pharmaceutics · 2022Article
- Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies.Theranostics · 2022Review
- Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes.International journal of molecular sciences · 2021Article
- Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?Pharmaceutics · 2020Review
- Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy.Pharmaceutics · 2020Article
- Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.International journal of nanomedicine · 2020Review
- Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting.Biochemistry and biophysics reports · 2019Article
- Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.International journal of nanomedicine · 2019Review
- Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis.Advanced pharmaceutical bulletin · 2018Article
- Overcoming clofazimine intrinsic toxicity: statistical modelling and characterization of solid lipid nanoparticles.Journal of the Royal Society, Interface · 2018Article
- Article
- Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.Acta biomaterialia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present work was to develop and optimize surface-functionalized solid lipid nanoparticles (SLNs) for improvement of the therapeutic index of dapsone (DAP), with the application of a design of experiments. The formulation was designed to target intestinal microfold (M-cells) as a strategy to increase internalization of the drug by the infected macrophages. DAP-loaded SLNs and mannosylated SLNs (M-SLNs) were successfully developed by hot ultrasonication method employing a three-level, three-factor Box-Behnken design, after the preformulation study was carried out with different lipids. All the formulations were systematically characterized regarding their diameter, polydispersity index (PDI), zeta potential (ZP), entrapment efficiency, and loading capacity. They were also subjected to morphological studies using transmission electron microscopy, in vitro release study, infrared analysis (Fourier transform infrared spectroscopy), calorimetry studies (differential scanning calorimetry), and stability studies. The diameter of SLNs, SLN-DAP, M-SLNs, and M-SLN-DAP was approximately 300 nm and the obtained PDI was <0.2, confirming uniform populations. Entrapment efficiency and loading capacity were approximately 50% and 12%, respectively. Transmission electron microscopy showed spherical shape and nonaggregated nanoparticles. Fourier transform infrared spectroscopy was used to confirm the success of mannose coating process though Schiff's base formation. The variation of the ZP between uncoated (approximately -30 mV) and mannosylated formulations (approximately +60 mV) also confirmed the successful coating process. A decrease in the enthalpy and broadening of the lipid melting peaks of the differential scanning calorimetry thermograms are consistent with the nanostructure of the SLNs. Moreover, the drug release was pH-sensitive, with a faster drug release at acidic pH than at neutral pH. Storage stability for the formulations for at least 8 weeks is expected, since they maintain the original characteristics of diameter, PDI, and ZP. These results pose a strong argument that the developed formulations can be explored as a promising carrier for treating leprosy with an innovative approach to target DAP directly to M-cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.